医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

SanBio Primary Researcher Receives 2017 Smithsonian American Ingenuity Award

2018年01月04日 PM11:00
このエントリーをはてなブックマークに追加


 

MOUNTAIN VIEW, Calif.

SanBio, Inc., a leader in regenerative cell therapies for neurological disorders, joins the Smithsonian Institution in recognizing Stanford University’s Dr. Gary Steinberg, chair of neurosurgery, for his pioneering research in the treatment of stroke patients. Steinberg received the Smithsonian’s prestigious American Ingenuity Award in Life Sciences for his unrelenting and unconventional approach to helping stroke patients regain motor function. Steinberg was the primary investigator in SanBio’s Phase 1/2a clinical trial in which stroke patients receiving SB623 demonstrated clinically significant improvement in motor function.

Said Dr. Damien Bates, Chief Medical Officer and Head of Research at SanBio, “This well-deserved recognition of Dr. Steinberg’s exemplary career and ongoing research shines light on the potential of stem cell therapies like SB623 to treat patients suffering from chronic physical impairments following a stroke.”

Dr. Steinberg was honored in the Life Sciences category for his commitment to neurological research and stroke patients. He also received recognition in Smithsonian magazine.

About SanBio, Inc. (SanBio)
SanBio is a regenerative medicine company headquartered in Tokyo, Japan, and Mountain View, California, with cell-based products in various stages of research, development, and clinical trials. Its proprietary cell-based product, SB623, is currently in a Phase 2b clinical trial for treatment of chronic motor impairments resulting from stroke with its joint development partner, Sumitomo Dainippon Pharma Co., Ltd., in the United States and Canada. SanBio is also implementing a global Phase 2 clinical trial in the United States and Japan using SB623 for treatment of motor impairment resulting from traumatic brain injury. More information about SanBio, Inc. is available at http://sanbio.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180104005262/en/

CONTACT

For SanBio, Inc.
Kris Patrow, 612-455-1748
Kris.Patrow@PadillaCo.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田薬品工業によるシャイアーの買収案を日本の公正取引委員会が承認
  • 武田拟收购Shire plc获得日本公平交易委员会批准
  • James Till教授因干细胞发现而荣获2018年度江户川Niche奖
  • Investigational Subcutaneous Formulation of Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis
  • Brightree发布面向居家医疗器械的首个患者App